Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 31, 2013, Pages 12786-12791

  Seeger Nukpezah, Tamina ^a   Proia, David A ^b   Egleston, Brian L ^a   Nikonova, Anna S ^a   Kent, Tatiana ^a   Cai, Kathy Q ^a   Hensley, Harvey H ^a   Ying, Weiwen ^b   Chimmanamada, Dinesh ^b   Serebriiskii, Ilya G ^a   Golemis, Erica A ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b Synta Pharmaceuticals Corp   (United States)

Author keywords

Ganetespib; HSP90 inhibitor; PKD

Indexed keywords

CYCLIN DEPENDENT KINASE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GANETESPIB; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDES AND PROTEINS; POLYCYSTIC KIDNEY DISEASE 1 PROTEIN; POLYCYSTIC KIDNEY DISEASE 2 PROTEIN; PROTEIN KINASE B; STA 2842; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL PROLIFERATION; GENE MUTATION; GENE OVEREXPRESSION; KIDNEY CELL; KIDNEY DEVELOPMENT; KIDNEY POLYCYSTIC DISEASE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

GANETESPIB; HSP90 INHIBITOR; PKD;

ANIMALS; CYSTS; DISEASE MODELS, ANIMAL; HSP90 HEAT-SHOCK PROTEINS; KIDNEY; MICE; MICE, KNOCKOUT; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROTEOLYSIS; SIGNAL TRANSDUCTION; TRPP CATION CHANNELS;

EID: 84881093725     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1301904110     Document Type: Article

References (26)

1. Harris PC, Torres VE (2009) Polycystic kidney disease. Annu Rev Med 60:321-337.
2. Grantham JJ, Nair V, Winklhoffer F (2000) Cystic diseases of the kidney. Brenner & Rector's The Kidney, ed Brenner BM (WB Saunders, Philadelphia), Vol 2, pp 1699-1730.
3. Torres VE, Harris PC (2006) Mechanisms of Disease: Autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2(1):40-55, quiz 55.
4. Sweeney WE, Jr., von Vigier RO, Frost P, Avner ED (2008) Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 19(7):1331-1341.
5. Shillingford JM, et al. (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 103(14):5466-5471.
6. Astsaturov I, et al. (2010) Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal 3(140):ra67.
7. Berns K, et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4): 395-402.
8. Taipale M, et al. (2012) Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell 150(5):987-1001.
9. Porter JR, Fritz CC, Depew KM (2010) Discovery and development of Hsp90 inhibitors: A promising pathway for cancer therapy. Curr Opin Chem Biol 14(3):412-420.
10. Grantham JJ (1990) Polycystic kidney disease: Neoplasia in disguise. Am J Kidney Dis 15(2):110-116.
11. Taipale M, Jarosz DF, Lindquist S (2010) HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nat Rev Mol Cell Biol 11(7):515-528.
12. Piontek K, Menezes LF, Garcia-Gonzalez MA, Huso DL, Germino GG (2007) A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med 13(12):1490-1495.
13. Torres VE, Harris PC (2009) Autosomal dominant polycystic kidney disease: The last 3 years. Kidney Int 76(2):149-168.
14. Ying W, et al. (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11(2):475-484.
15. Piontek KB, et al. (2004) A functional floxed allele of Pkd1 that can be conditionally inactivated in vivo. J Am Soc Nephrol 15(12):3035-3043.
16. Neckers L (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8(4, Suppl):S55-S61.
17. Cheng Q, et al. (2012) Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res 14(2):R62.
18. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10(8):537-549.
19. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R (1998) Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stresssensitive complex with HSF1. Cell 94(4):471-480.
20. Socinski MA, et al. (2013) A multicenter Phase II study of ganetespib monotherapy in patients with genotypically-defined advanced non-small cell lung cancer. Clin Cancer Res 19(11):3068-3077.
21. Luo W, et al. (2007) Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci USA 104(22): 9511-9516.
22. Luo W, Sun W, Taldone T, Rodina A, Chiosis G (2010) Heat shock protein 90 in neurodegenerative diseases. Mol Neurodegener 5:24.
23. Shimp SK, 3rd, et al. (2012) Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus. Cell Mol Immunol 9(3):255-266.
24. Plotnikova OV, Pugacheva EN, Golemis EA (2011) Aurora A kinase activity influences calcium signaling in kidney cells. J Cell Biol 193(6):1021-1032.
25. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT (2010) Identification of optimal drug combinations targeting cellular networks: Integrating phospho-proteomics and computational network analysis. Cancer Res 70(17):6704-6714.
26. Acquaviva J, et al. (2012) Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther 11(12):2633-2643.